









Markets
/
Stocks
/
nasdaq-goss
/

Gossamer Bio Inc

GOSS

3.080USD

+0.090+3.01%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

700.15MMarket Cap

LossP/E TTM



Gossamer Bio Inc

3.080

+0.090+3.01%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-18

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

67 / 506

Overall Ranking

167 / 4721

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 9 analysts

Buy

Current Rating

8.857

Target Price

+196.23%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Its product candidate Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. In contrast to the three classes of marketed vasodilatory therapies for PAH, its seralutinib has the potential to reverse pathological remodeling by addressing mechanisms that underlie PAH. Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways. In addition to PAH, seralutinib holds the potential as a therapeutic option for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Undervalued

The company’s latest PE is -5.03, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 183.64M shares, decreasing 24.41% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 11.41M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-18

The company's current financial score is 6.32, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 11.49M, representing a year-over-year decrease of 88.01%, while its net profit experienced a year-over-year decrease of 177.74%.

Score

Industry at a Glance

Previous score

6.32

Change



Financials

4.06

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.03

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.24

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.04

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.22

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-18

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -4.88, which is -24.70% below the recent high of -3.68 and -1.61% above the recent low of -4.96.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 67/506

No Data

Earnings Forecast

Currency: USD Updated：2025-09-18

The company’s current earnings forecast score is 8.44, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Gossamer Bio Inc is 9.00, with a high of 15.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

8.44

Change

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts

Buy

Current Rating

8.857

Target Price

+196.23%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Gossamer Bio Inc

GOSS

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-18

The company’s current price momentum score is 8.99, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 3.77 and the support level at 2.05, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.99

Change

0.04

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.017

Buy

RSI(14)

61.722

Neutral

STOCH(KDJ)(9,3,3)

52.414

Sell

ATR(14)

0.308

High Vlolatility

CCI(14)

32.386

Neutral

Williams %R

42.449

Buy

TRIX(12,20)

2.091

Sell

StochRSI(14)

10.810

Oversold

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

3.182

Sell

MA10

3.085

Sell

MA20

2.763

Buy

MA50

2.206

Buy

MA100

1.699

Buy

MA200

1.363

Buy

Institutional Confidence

Currency: USD Updated：2025-09-18

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 80.76%, representing a quarter-over-quarter increase of 1.87%. The largest institutional shareholder is The Vanguard, holding a total of 11.41M shares, representing 5.02% of shares outstanding, with 13.33% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Octagon Capital Advisors LP

18.35M

New Enterprise Associates (NEA)

18.09M

The Vanguard Group, Inc.

Star Investors

10.08M

+0.50%

ARCH Venture Partners

8.06M

Fidelity Management & Research Company LLC

7.59M

-4.29%

Acadian Asset Management LLC

6.36M

+24.55%

683 Capital Management LLC

6.10M

-12.54%

Samsara BioCapital, LLC

6.13M

Palo Alto Investors LP

6.28M

-0.00%

Risk Assessment

Currency: USD Updated：2025-09-18

The company’s current risk assessment score is 3.32, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.97. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.